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effects of the 315 side chain on the inhibitor sensitivityA Hot Spot for Protein Kinase
of several kinase families were studied before the directInhibitor Sensitivity medical relevance of the hot spot was elucidated. Young
and coworkers [7] and Goedert and coworkers [8] showed
that the sensitivity of mitogen-activated protein kinases
to pyridinylimidazole inhibitors is highly dependent on the
ATP binding site-directed protein kinase inhibitors are nature of the amino acid at position 315. In a similar
potent weapons in the war on cancer. However, spe- vein, Shokat and coworkers reported that both tyrosine
cific mutations at an inhibitor-sensitivity “hot spot” and serine/threonine kinases could be sensitized to the
can render these molecules ineffective. In this issue nominally Src-family-selective inhibitor PP1 (Figure 1)
of Chemistry & Biology, Daub and coworkers have through the introduction of small side chains at position
used an array of known kinase inhibitors to systemati- 315 [9]. These studies led to the generation of an “or-
cally characterize the desensitizing effects of hot spot thogonal” inhibitor approach, which can be used to spe-
mutations [1]. cifically target protein kinases that have been rationally
mutated at position 315 [10]. More recent studies have
The ubiquity of the protein kinases in anticancer thera- shown that BCR-Abl’s sensitivity to PD180970 (a pyr-
peutic research is difficult to overstate [2]. Protein ki- ido[2,3-d]pyrimidine) [11] and the PD153035-sensitivity
nase-catalyzed protein phosphorylation controls as- (a 4-anilinoquinazoline) of EGFR are also highly depen-
pects of essentially every known eukaryotic signaling dent on the side chain at position 315 [12]. If any con-
pathway, and aberrant regulation of kinase activity has stant theme emerges from these studies, it is that
been widely implicated in oncogenesis. It is no longer smaller amino acid side chains at 315 generally render
simply a truism that small molecule protein kinase inhibi- a kinase more susceptible to inhibition by compounds
tors may be important anticancer agents—it is well- that are capable of exploiting the open “gate.” While
established truth. STI571 has received wide attention in minor exceptions exist, this generalization holds re-
both the scientific and mainstream press as the first markably true over multiple kinase families.
“target-based” cancer therapeutic (Figure 1) [3]. This Daub and coworkers use various inhibitor scaffolds
molecule now represents a critical mode of treatment to develop a more complete picture of the relationship
for chronic myelogenous leukemia (CML). More recent between the nature of the 315 side chain and the sensi-
developments have shown that kinase inhibitor-based tivity profile of protein kinases [1]. The authors clearly
cancer treatment extends beyond CML. In the last year, demonstrate that the importance of the 315 position as
two different inhibitors of epidermal growth factor re- a determinant for kinase inhibitor sensitivity extends
ceptor (EGFR) kinase have been approved for clinical further than had been previously recognized. They use
use in the U.S.: ZD1839 (Gefitinib) for nonsmall cell lung as their starting point the “natural” C to T mutation that
cancer and Cetuximab for colorectal cancer. In addition, renders BCR-Abl insensitive to inhibition by STI571. The
roughly a dozen other members of the protein kinase equivalent base mutation (which, of course, leads to
superfamily are the putative drug targets in ongoing different amino acid changes in different kinases) also
anticancer clinical trials [2]. has profound effects on the sensitivity of EGFR (T766M)
The sobering fact buried in this good news is that and PDGFR (T681I). Critically, the threonine to methio-
protein kinases can acquire insensitivity to small mole- nine mutation in EGFR desensitizes the kinase to inhibi-
cule inhibitors through amino acid mutations in the ki- tion by ZD1839. This result highlights the possibility that
nase active site. This phenomenon has been most thor- ZD1839-resistant kinases could emerge in a fashion that
oughly characterized for STI571’s target, BCR-Abl, a is exactly analogous to the emergence of STI571-resis-
constitutively active protein kinase fusion protein that tant BCR-Abl. The authors also show that mutation of
is thought to be the causative agent of CML [4]. STI571- the corresponding PDGFR position to isoleucine de-
resistant CML patients harbor a variety of mutations in sensitizes that receptor tyrosine kinase to AG1296,
the kinase active site-encoding region of the BCR-ABL STI571, PP1, and PP58 (see Figures 1 and 2) and that
oncogene. Prevalent among these is a single base muta- similar hot spot methionine mutations in c-Src and FGFR
tion (C to T) that converts amino acid 315 from threonine also desensitize those kinases to PP58. Moreover, the
to isoleucine, a change in the BCR-Abl ATP binding site authors show that the indolinone class of molecules
that precludes molecular recognition of STI571. (exemplified by SU6656) represents an exception to the
Interestingly, the existence of a kinase inhibitor-sensi- general “big is bad” rule, i.e., indolinones can inhibit
tivity hot spot was known prior to the discovery of STI571 kinases that possess large side chains at position 315.
resistance in CML. Position 315 (c-Abl numbering) had The structural basis for the indolinone exception is clear:
been previously termed a “molecular gate” that controls these molecules do not extend into the extra binding
access to a portion of the kinase active site that is not pocket that is exploited by the other inhibitor classes;
used by ATP (see Figure 2) [5]. Kinase/inhibitor cocrystal they do not attempt to get past the “gate” [13].
structures have revealed that many potent kinase inhibi- What to Do with All of These Mutant-Specific Inhibitor
tors make use of this “extra” pocket, allowing them to Data? Daub and coworkers use their inhibitor-sensitivity
data to devise a clever chemical genetic method forcompete with ATP for active site binding affinity [6]. The
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signaling cascades and for the identification of c-Src
substrates.
What Else to Do with All of These Mutant-Specific
Inhibitor Data? In theory, drugs that are specific for
naturally occurring mutant oncogene products could be
designed. However, the labor intensity of such an under-
taking coupled with the small number of patients that
express a given mutant kinase would most likely render
this approach impractical. Nonetheless, emerging data
suggest that mutant-specific kinase inhibition data may
be very helpful in tailoring individual treatment programs
for cancer patients. Paez et al. recently reported that a
leucine to arginine mutation in the kinase active site
confers increased ZD1839 sensitivity upon EGFR [15].
This mutation was discovered by sequencing the EGFR
genes of lung cancer tumors. Importantly, presence of
Figure 1. Chemical Structures of Some of the Kinase Inhibitors Dis- the mutation correlates with efficacy of treatment with
cussed in This Article
ZD1839. Paez et al. suggest that similar genetic data
The structure of PP58 is shown in Figure 2.
may prove predictive for gauging a patient’s prospects
for effective lung cancer treatment with ZD1839. These
results highlight the importance of gaining a molecularelucidating the functions of c-Src, a tyrosine kinase that
level understanding of the relationship between kinaseis also a cancer drug target [14]. They show that the
active site mutations and inhibitor sensitivity. They alsoPP58 (a broad spectrum kinase inhibitor) can inhibit the
foretell a future when doctors and patients will knowc-Src-inhibitory kinase CSK. Thus, expression of PP58-
precisely which kinase inhibitors will successfully targetdesensitized c-Src in cells creates a system in which
which tumors, allowing futile treatments to be avoided—Src is specifically activated through inhibition of CSK.
something to look forward to, indeed.Since the PP58-desensitized c-Src is (presumably) the
only cellular kinase that is activated by the addition of
PP58, this system allows for c-Src-specific cell signaling
Anthony C. Bishopevents to be studied in isolation. This (rather counterin-
Amherst Collegetuitive) method of activating c-Src kinase through appli-
Department of Chemistrycation of a general kinase inhibitor may prove to be
Amherst, Massachusetts 01002a useful tool for the deconvolution of c-Src-mediated
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the original termini, effectively splitting the expressedRecombination
protein in two. This process generates a library of plas-of Fragmented Proteins mids that encode all possible fragment pairs (224 in all
for Trp1p).
To isolate sensors of protein-protein interactions, the
N- and C-terminal fragments of Trp1p were each pro-
Directed evolution is a powerful method for generating duced as C-terminal and N-terminal fusions, respec-
novel molecules with desirable properties. In devel- tively, to independently interacting polypeptides. The
oping a new sensor to screen for protein-protein inter- plasmid library was transformed into trp1 yeast (which
actions, Tafelmeyer et al. [1] report a clever strategy require an added source of Trp1p activity for survival in
to evolve heterodimeric “split proteins” from a mono- the absence of tryptophan) to select for functional split-
mer in this issue of Chemistry & Biology. Trp1p pairs. In this selection system, the only cells that
grow are those in which the fragment pairs can reconsti-
tute Trp1p activity.Two individually inactive protein fragments can some-
The sequences identified by functional selection musttimes recombine to form active heterodimers. Perhaps
be further screened to identify false positives (Figure 1).the most notable example of such a split-protein system
In this case, positives were subjected to a second roundis ribonuclease S (RNase S), a tightly associated hetero-
of selection after removing the fusion partner from thedimer that is generated from two proteolytic fragments
N-terminal fragment of Trp1p. Those split Trp1ps thatproduced by the limited digestion of ribonuclease A by
either associate too tightly or possess one fragmentthe protease subtilisin [2]. RNase S is a longstanding
large enough to possess activity by itself will comple-workhorse in both protein chemistry [3] and biotechnol-
ment the mutation independent of the interaction be-ogy [4]. In addition, a rationally designed split in ubiquitin
tween the fusion partners and can thus be eliminated.was used to develop a sensor for screening protein-
Out of a library of approximately 1600 clones, Tafel-protein interactions [5] and has also inspired other
meyer et al. identified four Trp1p fragment pairs thatsensors based on complementation of fragment pairs
survived the first selection but not the second. These
derived from a few other proteins. Muir et al. recently
four split Trp1ps thus function as sensors of protein-
developed a split-protein application that harnesses a
protein interactions [1].
naturally heterodimeric intein to facilitate the in vivo liga- Trp1p is a smart choice for this proof-of-principle ex-
tion of an endogenously produced protein with an exo- periment for generating tailored split proteins. In addi-
genously produced molecule [6]. Despite their diverse tion to the availability of a selection system for yeast
uses, the number of available split proteins appears cell growth, there is a wealth of knowledge about the
quite limited. structure and engineering of this (/)8-barrel scaffold.
The challenge of finding suitable fragment pairings The existence of enzymatically active variants that have
may have thus far prevented more widespread applica- been either circularly permuted (in the homolog of Trp1p
tion of split-protein systems. By performing activity se- from Escherichia coli) [8] or rationally fragmented (in
lections on combinatorial libraries of fragment pairs, S. cerevisiae Trp1p) [9] augured well for the success of
Tafelmeyer et al. [1] have surmounted this obstacle. In this approach.
this way, they have identified a series of fragmentation For developing a split Trp1p that can act as a sensor
sites within the (/)8-barrel enzyme N-(5-phosphoribo- for protein-protein interactions, the trick is to isolate
syl) anthranilate isomerase, Trp1p, from Saccharomyces fragments capable of only conditional heterodimeriza-
cerevisiae that can be used to make a sensor for protein- tion. Heterodimers with a sufficiently high Kd in vivo
protein interactions (Figure 1). In essence, their strategy require the interaction of fusion partners to raise the
for library construction adapts an established method effective concentration of one fragment relative to the
for generating random circular permutations of a given other. The rationally designed split Trp1p engineered by
protein sequence. In this method, a circularized gene is Eder and Kirschner [9] forms a complex between a large,
randomly linearized to generate new termini [7]. Tafel- well-structured N-terminal fragment and a small, poorly
meyer et al. modified this procedure by afterwards in- structured C-terminal fragment with a Kd of 0.2 M
serting a DNA sequence containing a successive termi- and near-native catalytic efficiency. This observation
nator and promoter between the sequence encoding may explain why most of the false positives identified
the original N and C termini of Trp1p. By this scheme, in the search for sensors of protein-protein interactions
a circular permutation generates a single break in the were heterodimers that possessed relatively large N-ter-
minal fragments [1]. The affinity and activity of Eder andprimary sequence and is followed by the unmasking of
